Latest Investments News

Cluey Ltd reported a 50% improvement in EBITDA and its first positive operating cash flow quarter in FY25, driven by cost efficiencies and a return to student growth. The company is now pivoting towards AI-enabled product innovation to fuel sustainable expansion.

Acrux Ltd reported a 44% revenue decline and a modest increase in net loss for FY25, while expanding its US topical generics portfolio and entering the Saudi Arabian market. The company signals a strategic pivot amid intensifying competition and lower returns.

Cluey Ltd has marked a pivotal year with a $4.4 million EBITDA improvement and its first positive operating cash flow quarter, alongside renewed student growth. The company is now pivoting towards AI-driven product expansion to sustain momentum.

Cluey Ltd reported a significantly reduced loss for FY25 alongside an 11% increase in new students and achieved positive operating cash flow in Q4, signaling progress in its path to profitability.

K2 Asset Management posted a 17% revenue increase and returned to profitability in FY25, declaring a fully franked dividend and signalling plans for mergers and acquisitions to accelerate expansion.

K2 Asset Management Holdings Ltd has reported a strong financial year ending June 2025, with revenues up 17% and a return to profitability, alongside a fully franked dividend declaration.

Next Science Limited reported a 7% revenue decline and a 20% reduction in net loss for H1 2025, alongside a major $50 million asset sale agreement with OSARTIS GmbH. The transaction, approved by shareholders, signals a strategic pivot for the biofilm-focused medical device company.

Tryptamine Therapeutics reported a $5.33 million loss for FY25 while progressing key clinical trials of its psychedelic therapies and strengthening its leadership team. The company secured $6 million in funding and launched a world-first trial targeting Binge Eating Disorder.

AF Legal Group has reported a strong FY25 with 27% revenue growth and a 77% increase in normalised profit, driven by strategic acquisitions and operational improvements.

Boss Energy reports a strong financial foundation with positive operating cash flow and a robust balance sheet in FY2025, its first full year of uranium production. Despite a net loss driven by non-cash costs, the company positions itself for growth amid rising uranium prices.

Metal Powder Works Limited reported a 15% revenue decline and a 224% surge in net loss for FY2025, driven by acquisition costs and a pivot towards long-term contracts.

LTR Pharma Limited (ASX, LTP) reported significant progress in FY25, advancing its novel intranasal treatments for erectile dysfunction and expanding its commercial footprint in Australia and the US. The company secured key partnerships and capital raises, positioning itself for regulatory milestones and global market entry.